Merck & Company Inc (MRK)vsSimulations Plus Inc (SLP)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
SLP
Simulations Plus Inc
$18.42
0.00%
HEALTHCARE · Cap: $372.74M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 81024% more annual revenue ($66.57B vs $82.06M). SLP leads profitability with a 9.9% profit margin vs 4.8%. MRK appears more attractively valued with a PEG of 2.64. SLP earns a higher WallStSmart Score of 55/100 (C-).
MRK
Hold36
out of 100
Grade: F
SLP
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Margin of Safety
+59.6%
Fair Value
$29.98
Current Price
$18.42
$11.56 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Strong operational efficiency at 22.8%
Earnings expanding 46.7% YoY
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Smaller company, higher risk/reward
Expensive relative to growth rate
Premium valuation, high expectations priced in
ROE of -38.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : SLP
The strongest argument for SLP centers on Debt/Equity, Altman Z-Score, Price/Book.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : SLP
The primary concerns for SLP are Market Cap, PEG Ratio, P/E Ratio. A P/E of 46.1x leaves little room for execution misses.
Key Dynamics to Monitor
SLP carries more volatility with a beta of 1.33 — expect wider price swings.
SLP is growing revenue faster at 7.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
SLP scores higher overall (55/100 vs 36/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Simulations Plus Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling, simulation, and prediction of molecule properties using artificial intelligence and machine learning technology worldwide. The company is headquartered in Lancaster, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?